Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line

Leukemia volume 23, pages 1935–1938 (2009)Cite this article

The wingless-type (Wnt) signalling pathway is involved in leukemogenesis and the glycogen-synthase kinase 3β has been reported to control both β-catenin and nuclear factor (NF)-κB.1 Thus, if NF-κB and Wnt pathways are really controlled by common genes, drugs able to modulate one or both of these signals would represent innovative therapeutic tools in treatment of myeloproliferative disorders.

NF-κB is constitutively activated in acute myeloid leukemia, high-risk myelodysplastic syndromes and chronic myeloproliferative Ph-negative disorders.2 Histone deacetylase inhibitors (HDACIs) seem to be able to interfere with the NF-κB pathway.3 Currently available HDACIs include valproic acid, depsipeptide, LBH589, ITF2357 and vorinostat. Recently, oral formulation of vorinostat has been assessed in a phase-I trial, recruiting 41 patients with relapsed or refractory leukemia and myelodysplastic syndromes, with promising results.4 Recently, in 41% of acute myeloid leukemia and myelodysplastic syndrome cases, malignant cells stained positively for β-catenin, with significant association between Wnt activation and M7 subtypes, deletion of chromosome 7 and complex karyotypes, conditions significantly associated with a poorer prognosis.5

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR . Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86–90.

    Article  CAS  Google Scholar 

  2. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301–2307.

    Article  CAS  Google Scholar 

  3. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB . Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281: 5612–5622.

    Article  CAS  Google Scholar 

  4. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060–1066.

    Article  CAS  Google Scholar 

  5. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2008; 140: 394–401.

    Article  CAS  Google Scholar 

  6. Galimberti S, Canestraro M, Khan R, Buda G, Orciuolo E, Guerrini F et al. Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia 2008; 22: 628–631.

    Article  CAS  Google Scholar 

  7. Galimberti S, Canestraro M, Pacini S, Fazzi R, Orciuolo E, Trombi L et al. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res 2008; 32: 103–112.

    Article  CAS  Google Scholar 

  8. Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006; 108: 965–973.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Pisa, Italy

    S Galimberti, M Canestraro, F Guerrini, E Ciabatti & M Petrini

  2. Haematology Division, Department of Oncology, University of Modena and Reggio Emilia, Modena, Italy

    R Maffei & R Marasca

  3. Department of Experimental Pathology, Pathology Section, University of Pisa, Pisa, Italy

    S Piaggi

Authors
  1. S Galimberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Canestraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Maffei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Marasca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Guerrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Piaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Ciabatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Petrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Galimberti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galimberti, S., Canestraro, M., Maffei, R. et al. Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line. Leukemia 23, 1935–1938 (2009). https://doi.org/10.1038/leu.2009.119

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.119

This article is cited by

Search

Advanced search

Quick links